Conditions: Hemophilia A
Keywords: Hemophilia A
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 208
Healthy volunteers: no

Brief summary:
The study will be investigating safety in patients who switch to ReFacto AF from ReFacto and other Factor VIII products.

Detailed description:
The trial was terminated prematurely on 28 March 2013, due to the inability to recruit the planned number of subjects. The decision to terminate the trial was not based on any safety or efficacy concerns and agreement to close the study in March 2013 was agreed with EMA prior to closure activity.

Arms:
arm 1: None

Interventions: intervention 1: moroctocog alfa (AF-CC) (ReFacto AF) intervention 2: Laboratory tests
Intervention descriptions: intervention 1: Providing moroctocog alfa (AF-CC) as test article for use during this study. intervention 2: Laboratory samples are collected during study visits, in order to collect safety and efficacy data related to the administration of test article.

Protocol document: